Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 8/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | PDE4A | P27815 | 2/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11699822 | 1.00 | MAPK1 (0.58) | MAPK1RXFP1ADORA2BLMNASMN1; SMN2 | |
| SCHEMBL11702656 | 1.00 | MAPK1 (0.58) | MAPK1RXFP1ADORA2BLMNASMN1; SMN2 | |
| SCHEMBL11703954 | 1.00 | MAPK1 (0.58) | MAPK1RXFP1ADORA2BLMNASMN1; SMN2 | |
| SCHEMBL684387 | 0.99 | MAPK1 (0.60) | MAPK1RXFP1ADORA2BLMNASMN1; SMN2 | |
| SCHEMBL11704186 | 0.94 | MAPK1 (0.53) | MAPK1RXFP1ADORA2BLMNASMN1; SMN2 | |
| SCHEMBL11704172 | 0.94 | MAPK1 (0.53) | MAPK1RXFP1ADORA2BLMNASMN1; SMN2 | |
| SCHEMBL11705193 | 0.93 | RXFP1 (0.61) | MAPK1RXFP1ADORA2BLMNASMN1; SMN2 | |
| SCHEMBL11699867 | 0.91 | MAPK1 (0.58) | MAPK1RXFP1ADORA2BLMNASMN1; SMN2 | |
| SCHEMBL11635023 | 0.89 | ADORA2B (0.55) | MAPK1RXFP1ADORA2BLMNASMN1; SMN2 | |
| SCHEMBL11635125 | 0.88 | ADORA2B (0.58) | MAPK1RXFP1ADORA2BLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3935196-A | Useful pro-drug forms of theophylline | INTERX RESEARCH CORPORATION (US) | 1976-01-27 | — | — | US | claimed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-4002756-A | Useful pro-drug forms of theophylline | INTERX RESEARCH CORPORATION (US) | 1977-01-11 | — | — | US | disclosed |
| US-4000132-A | REACTION WITH CARBOXYLIC ACID, PHOSGENE, OR THIONYL CHLORIDE | INTERX RESEARCH CORPORATION (US) | 1976-12-28 | — | — | US | disclosed |
| US-3935196-A | Useful pro-drug forms of theophylline | INTERX RESEARCH CORPORATION (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | MAPK1 470/4885RXFP1 211/4885ADORA2B 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.